|Videos|November 14, 2016

The Arms Race Against Bacteria

Marcos Pires, PhD, assistant professor at Lehigh University, discusses the threat of antibiotic resistance.

Marcos Pires, PhD, assistant professor at Lehigh University, discusses the threat of antibiotic resistance.

Interview Transcript (slightly modified for readability)

“One question that is [on] everyone’s mind when we think about coming up with new antimicrobial strategies is the propensity for the development of resistance, and that could come about from misuse [or] overuse of a particular therapy. I think it’s fair to say that any therapy that gets overused will likely fall prey to the same idea that, at the end of the day, any antimicrobial therapy is inherently putting a selective pressure, and only the strongest members of that population (in this case bacteria) will survive.

I think we have to start thinking about drug resistance as something that is just part of the process. It’s not to discourage drug discovery and development; it’s to think about if we can diversify the portfolio of drugs that we have, then we have more chances to go after an infection.

That proves to be the case during the 1960's, 70's, and even early 80's: when we had a number of antibiotics that were all active, drug resistance really wasn’t an issue. So, I think it is a question of numbers; if we can get enough different drugs with unique mechanisms of action, I think we can win this arms race against bacteria.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.